Shares of Atrion Co. (NASDAQ:ATRI) have been given an average broker rating score of 5.00 (Strong Sell) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a strong sell recommendation.
Zacks has also assigned Atrion an industry rank of 219 out of 265 based on the ratings given to related companies.
Separately, BidaskClub lowered shares of Atrion from a “sell” rating to a “strong sell” rating in a research note on Tuesday, January 9th.
Atrion (NASDAQ ATRI) opened at $602.10 on Monday. The stock has a market cap of $1,111.80, a PE ratio of 30.55 and a beta of 0.70. Atrion has a one year low of $459.50 and a one year high of $694.00.
Atrion (NASDAQ:ATRI) last issued its earnings results on Tuesday, February 27th. The medical instruments supplier reported $4.66 earnings per share (EPS) for the quarter. The company had revenue of $34.02 million for the quarter. Atrion had a net margin of 24.96% and a return on equity of 19.53%.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Thursday, March 15th will be paid a $1.20 dividend. This represents a $4.80 annualized dividend and a dividend yield of 0.80%. The ex-dividend date is Wednesday, March 14th. Atrion’s dividend payout ratio (DPR) is presently 24.35%.
Several hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Atrion by 2.6% in the 4th quarter. BlackRock Inc. now owns 100,724 shares of the medical instruments supplier’s stock valued at $63,516,000 after purchasing an additional 2,549 shares during the last quarter. Neuberger Berman Group LLC boosted its stake in shares of Atrion by 4.0% in the 3rd quarter. Neuberger Berman Group LLC now owns 86,185 shares of the medical instruments supplier’s stock valued at $57,916,000 after purchasing an additional 3,291 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Atrion by 1.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 64,290 shares of the medical instruments supplier’s stock valued at $43,203,000 after purchasing an additional 1,022 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Atrion by 2.6% in the 4th quarter. Renaissance Technologies LLC now owns 59,700 shares of the medical instruments supplier’s stock valued at $37,647,000 after acquiring an additional 1,500 shares during the period. Finally, State Street Corp raised its position in shares of Atrion by 3.0% in the 2nd quarter. State Street Corp now owns 31,790 shares of the medical instruments supplier’s stock valued at $20,446,000 after acquiring an additional 919 shares during the period. 59.17% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/03/22/zacks-atrion-co-atri-receives-average-rating-of-strong-sell-from-brokerages.html.
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.
Get a free copy of the Zacks research report on Atrion (ATRI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.